nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—MTOR—ovarian cancer	0.65	1	CbGaD
Everolimus—CYP3A4—Topotecan—ovarian cancer	0.0102	0.354	CbGbCtD
Everolimus—CYP3A4—Vinorelbine—ovarian cancer	0.00718	0.25	CbGbCtD
Everolimus—CYP3A4—Paclitaxel—ovarian cancer	0.00504	0.175	CbGbCtD
Everolimus—CYP3A4—Docetaxel—ovarian cancer	0.00364	0.127	CbGbCtD
Everolimus—MTOR—myometrium—ovarian cancer	0.00278	0.0649	CbGeAlD
Everolimus—CYP3A4—Doxorubicin—ovarian cancer	0.00272	0.0945	CbGbCtD
Everolimus—MTOR—embryo—ovarian cancer	0.00268	0.0624	CbGeAlD
Everolimus—FKBP1A—myometrium—ovarian cancer	0.0025	0.0584	CbGeAlD
Everolimus—MTOR—epithelium—ovarian cancer	0.00218	0.051	CbGeAlD
Everolimus—FKBP1A—epithelium—ovarian cancer	0.00197	0.0458	CbGeAlD
Everolimus—MTOR—endometrium—ovarian cancer	0.00196	0.0457	CbGeAlD
Everolimus—FKBP1A—uterine cervix—ovarian cancer	0.00195	0.0454	CbGeAlD
Everolimus—Pimecrolimus—MTOR—ovarian cancer	0.00191	0.314	CrCbGaD
Everolimus—FKBP1A—decidua—ovarian cancer	0.00186	0.0433	CbGeAlD
Everolimus—MTOR—gonad—ovarian cancer	0.00182	0.0424	CbGeAlD
Everolimus—MTOR—uterus—ovarian cancer	0.00181	0.0421	CbGeAlD
Everolimus—FKBP1A—endometrium—ovarian cancer	0.00176	0.0411	CbGeAlD
Everolimus—FKBP1A—gonad—ovarian cancer	0.00163	0.0381	CbGeAlD
Everolimus—FKBP1A—uterus—ovarian cancer	0.00162	0.0379	CbGeAlD
Everolimus—MTOR—female reproductive system—ovarian cancer	0.00162	0.0378	CbGeAlD
Everolimus—MTOR—bone marrow—ovarian cancer	0.00153	0.0357	CbGeAlD
Everolimus—MTOR—female gonad—ovarian cancer	0.00148	0.0344	CbGeAlD
Everolimus—MTOR—vagina—ovarian cancer	0.00147	0.0342	CbGeAlD
Everolimus—FKBP1A—female reproductive system—ovarian cancer	0.00146	0.034	CbGeAlD
Everolimus—FKBP1A—bone marrow—ovarian cancer	0.00138	0.0321	CbGeAlD
Everolimus—FKBP1A—female gonad—ovarian cancer	0.00133	0.031	CbGeAlD
Everolimus—FKBP1A—vagina—ovarian cancer	0.00132	0.0308	CbGeAlD
Everolimus—MTOR—testis—ovarian cancer	0.00131	0.0305	CbGeAlD
Everolimus—Temsirolimus—MTOR—ovarian cancer	0.00129	0.212	CrCbGaD
Everolimus—FKBP1A—testis—ovarian cancer	0.00118	0.0275	CbGeAlD
Everolimus—Sirolimus—MTOR—ovarian cancer	0.00114	0.187	CrCbGaD
Everolimus—Tacrolimus—MTOR—ovarian cancer	0.00114	0.187	CrCbGaD
Everolimus—MTOR—lymph node—ovarian cancer	0.00095	0.0221	CbGeAlD
Everolimus—FKBP1A—lymph node—ovarian cancer	0.000854	0.0199	CbGeAlD
Everolimus—CYP3A4—female reproductive system—ovarian cancer	0.000477	0.0111	CbGeAlD
Everolimus—Temsirolimus—ABCB1—ovarian cancer	0.000222	0.0365	CrCbGaD
Everolimus—Tacrolimus—ABCB1—ovarian cancer	0.000195	0.0321	CrCbGaD
Everolimus—Sirolimus—ABCB1—ovarian cancer	0.000195	0.0321	CrCbGaD
Everolimus—Infestation—Epirubicin—ovarian cancer	6.28e-05	0.000389	CcSEcCtD
Everolimus—Bronchitis—Doxorubicin—ovarian cancer	6.27e-05	0.000388	CcSEcCtD
Everolimus—Dyspnoea—Paclitaxel—ovarian cancer	6.25e-05	0.000386	CcSEcCtD
Everolimus—Somnolence—Paclitaxel—ovarian cancer	6.23e-05	0.000385	CcSEcCtD
Everolimus—Myalgia—Docetaxel—ovarian cancer	6.2e-05	0.000383	CcSEcCtD
Everolimus—Arthralgia—Docetaxel—ovarian cancer	6.2e-05	0.000383	CcSEcCtD
Everolimus—Chest pain—Docetaxel—ovarian cancer	6.2e-05	0.000383	CcSEcCtD
Everolimus—Pancytopenia—Doxorubicin—ovarian cancer	6.19e-05	0.000383	CcSEcCtD
Everolimus—Nausea—Vinorelbine—ovarian cancer	6.19e-05	0.000383	CcSEcCtD
Everolimus—Renal failure—Epirubicin—ovarian cancer	6.18e-05	0.000382	CcSEcCtD
Everolimus—Dyspepsia—Paclitaxel—ovarian cancer	6.17e-05	0.000382	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	6.15e-05	0.000381	CcSEcCtD
Everolimus—Jaundice—Epirubicin—ovarian cancer	6.12e-05	0.000379	CcSEcCtD
Everolimus—Stomatitis—Epirubicin—ovarian cancer	6.12e-05	0.000379	CcSEcCtD
Everolimus—Urinary tract infection—Epirubicin—ovarian cancer	6.11e-05	0.000378	CcSEcCtD
Everolimus—Conjunctivitis—Epirubicin—ovarian cancer	6.11e-05	0.000378	CcSEcCtD
Everolimus—Neutropenia—Doxorubicin—ovarian cancer	6.1e-05	0.000377	CcSEcCtD
Everolimus—Dysuria—Doxorubicin—ovarian cancer	6.1e-05	0.000377	CcSEcCtD
Everolimus—Decreased appetite—Paclitaxel—ovarian cancer	6.09e-05	0.000377	CcSEcCtD
Everolimus—Dry mouth—Docetaxel—ovarian cancer	6.06e-05	0.000375	CcSEcCtD
Everolimus—Upper respiratory tract infection—Doxorubicin—ovarian cancer	6.06e-05	0.000375	CcSEcCtD
Everolimus—Gastrointestinal disorder—Paclitaxel—ovarian cancer	6.05e-05	0.000374	CcSEcCtD
Everolimus—Fatigue—Paclitaxel—ovarian cancer	6.04e-05	0.000374	CcSEcCtD
Everolimus—Pollakiuria—Doxorubicin—ovarian cancer	6.02e-05	0.000372	CcSEcCtD
Everolimus—Constipation—Paclitaxel—ovarian cancer	5.99e-05	0.000371	CcSEcCtD
Everolimus—Pain—Paclitaxel—ovarian cancer	5.99e-05	0.000371	CcSEcCtD
Everolimus—Haematuria—Epirubicin—ovarian cancer	5.99e-05	0.00037	CcSEcCtD
Everolimus—Hepatobiliary disease—Epirubicin—ovarian cancer	5.94e-05	0.000367	CcSEcCtD
Everolimus—Oedema—Docetaxel—ovarian cancer	5.94e-05	0.000367	CcSEcCtD
Everolimus—Epistaxis—Epirubicin—ovarian cancer	5.93e-05	0.000366	CcSEcCtD
Everolimus—Infection—Docetaxel—ovarian cancer	5.9e-05	0.000365	CcSEcCtD
Everolimus—Weight decreased—Doxorubicin—ovarian cancer	5.9e-05	0.000365	CcSEcCtD
Everolimus—Sinusitis—Epirubicin—ovarian cancer	5.89e-05	0.000365	CcSEcCtD
Everolimus—Hyperglycaemia—Doxorubicin—ovarian cancer	5.88e-05	0.000364	CcSEcCtD
Everolimus—Pneumonia—Doxorubicin—ovarian cancer	5.85e-05	0.000362	CcSEcCtD
Everolimus—Shock—Docetaxel—ovarian cancer	5.85e-05	0.000361	CcSEcCtD
Everolimus—Nervous system disorder—Docetaxel—ovarian cancer	5.83e-05	0.00036	CcSEcCtD
Everolimus—Thrombocytopenia—Docetaxel—ovarian cancer	5.82e-05	0.00036	CcSEcCtD
Everolimus—Infestation NOS—Doxorubicin—ovarian cancer	5.81e-05	0.000359	CcSEcCtD
Everolimus—Infestation—Doxorubicin—ovarian cancer	5.81e-05	0.000359	CcSEcCtD
Everolimus—Tachycardia—Docetaxel—ovarian cancer	5.8e-05	0.000359	CcSEcCtD
Everolimus—Feeling abnormal—Paclitaxel—ovarian cancer	5.78e-05	0.000357	CcSEcCtD
Everolimus—Skin disorder—Docetaxel—ovarian cancer	5.77e-05	0.000357	CcSEcCtD
Everolimus—Gastrointestinal pain—Paclitaxel—ovarian cancer	5.73e-05	0.000354	CcSEcCtD
Everolimus—Renal failure—Doxorubicin—ovarian cancer	5.71e-05	0.000353	CcSEcCtD
Everolimus—Haemoglobin—Epirubicin—ovarian cancer	5.67e-05	0.000351	CcSEcCtD
Everolimus—Jaundice—Doxorubicin—ovarian cancer	5.67e-05	0.00035	CcSEcCtD
Everolimus—Stomatitis—Doxorubicin—ovarian cancer	5.67e-05	0.00035	CcSEcCtD
Everolimus—Anorexia—Docetaxel—ovarian cancer	5.66e-05	0.00035	CcSEcCtD
Everolimus—Rhinitis—Epirubicin—ovarian cancer	5.65e-05	0.00035	CcSEcCtD
Everolimus—Conjunctivitis—Doxorubicin—ovarian cancer	5.65e-05	0.000349	CcSEcCtD
Everolimus—Urinary tract infection—Doxorubicin—ovarian cancer	5.65e-05	0.000349	CcSEcCtD
Everolimus—Hepatitis—Epirubicin—ovarian cancer	5.64e-05	0.000349	CcSEcCtD
Everolimus—Haemorrhage—Epirubicin—ovarian cancer	5.64e-05	0.000349	CcSEcCtD
Everolimus—Hypoaesthesia—Epirubicin—ovarian cancer	5.61e-05	0.000347	CcSEcCtD
Everolimus—Pharyngitis—Epirubicin—ovarian cancer	5.6e-05	0.000346	CcSEcCtD
Everolimus—Urinary tract disorder—Epirubicin—ovarian cancer	5.57e-05	0.000344	CcSEcCtD
Everolimus—Oedema peripheral—Epirubicin—ovarian cancer	5.56e-05	0.000344	CcSEcCtD
Everolimus—Hypotension—Docetaxel—ovarian cancer	5.55e-05	0.000343	CcSEcCtD
Everolimus—Haematuria—Doxorubicin—ovarian cancer	5.54e-05	0.000343	CcSEcCtD
Everolimus—Connective tissue disorder—Epirubicin—ovarian cancer	5.54e-05	0.000343	CcSEcCtD
Everolimus—Abdominal pain—Paclitaxel—ovarian cancer	5.54e-05	0.000343	CcSEcCtD
Everolimus—Body temperature increased—Paclitaxel—ovarian cancer	5.54e-05	0.000343	CcSEcCtD
Everolimus—Urethral disorder—Epirubicin—ovarian cancer	5.53e-05	0.000342	CcSEcCtD
Everolimus—Hepatobiliary disease—Doxorubicin—ovarian cancer	5.5e-05	0.00034	CcSEcCtD
Everolimus—Epistaxis—Doxorubicin—ovarian cancer	5.48e-05	0.000339	CcSEcCtD
Everolimus—Sinusitis—Doxorubicin—ovarian cancer	5.45e-05	0.000337	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Docetaxel—ovarian cancer	5.41e-05	0.000335	CcSEcCtD
Everolimus—Insomnia—Docetaxel—ovarian cancer	5.37e-05	0.000332	CcSEcCtD
Everolimus—Paraesthesia—Docetaxel—ovarian cancer	5.33e-05	0.00033	CcSEcCtD
Everolimus—Dyspnoea—Docetaxel—ovarian cancer	5.3e-05	0.000328	CcSEcCtD
Everolimus—Somnolence—Docetaxel—ovarian cancer	5.28e-05	0.000327	CcSEcCtD
Everolimus—Eye disorder—Epirubicin—ovarian cancer	5.27e-05	0.000326	CcSEcCtD
Everolimus—Haemoglobin—Doxorubicin—ovarian cancer	5.25e-05	0.000324	CcSEcCtD
Everolimus—Cardiac disorder—Epirubicin—ovarian cancer	5.23e-05	0.000324	CcSEcCtD
Everolimus—Flushing—Epirubicin—ovarian cancer	5.23e-05	0.000324	CcSEcCtD
Everolimus—Rhinitis—Doxorubicin—ovarian cancer	5.23e-05	0.000324	CcSEcCtD
Everolimus—Dyspepsia—Docetaxel—ovarian cancer	5.23e-05	0.000323	CcSEcCtD
Everolimus—Haemorrhage—Doxorubicin—ovarian cancer	5.22e-05	0.000323	CcSEcCtD
Everolimus—Hepatitis—Doxorubicin—ovarian cancer	5.22e-05	0.000323	CcSEcCtD
Everolimus—Hypoaesthesia—Doxorubicin—ovarian cancer	5.19e-05	0.000321	CcSEcCtD
Everolimus—Pharyngitis—Doxorubicin—ovarian cancer	5.18e-05	0.00032	CcSEcCtD
Everolimus—Decreased appetite—Docetaxel—ovarian cancer	5.16e-05	0.000319	CcSEcCtD
Everolimus—Hypersensitivity—Paclitaxel—ovarian cancer	5.16e-05	0.000319	CcSEcCtD
Everolimus—Urinary tract disorder—Doxorubicin—ovarian cancer	5.15e-05	0.000319	CcSEcCtD
Everolimus—Oedema peripheral—Doxorubicin—ovarian cancer	5.14e-05	0.000318	CcSEcCtD
Everolimus—Gastrointestinal disorder—Docetaxel—ovarian cancer	5.13e-05	0.000317	CcSEcCtD
Everolimus—Connective tissue disorder—Doxorubicin—ovarian cancer	5.13e-05	0.000317	CcSEcCtD
Everolimus—Fatigue—Docetaxel—ovarian cancer	5.12e-05	0.000317	CcSEcCtD
Everolimus—Angiopathy—Epirubicin—ovarian cancer	5.12e-05	0.000316	CcSEcCtD
Everolimus—Urethral disorder—Doxorubicin—ovarian cancer	5.12e-05	0.000316	CcSEcCtD
Everolimus—Immune system disorder—Epirubicin—ovarian cancer	5.09e-05	0.000315	CcSEcCtD
Everolimus—Mediastinal disorder—Epirubicin—ovarian cancer	5.08e-05	0.000314	CcSEcCtD
Everolimus—Pain—Docetaxel—ovarian cancer	5.08e-05	0.000314	CcSEcCtD
Everolimus—Constipation—Docetaxel—ovarian cancer	5.08e-05	0.000314	CcSEcCtD
Everolimus—Chills—Epirubicin—ovarian cancer	5.06e-05	0.000313	CcSEcCtD
Everolimus—Asthenia—Paclitaxel—ovarian cancer	5.03e-05	0.000311	CcSEcCtD
Everolimus—Alopecia—Epirubicin—ovarian cancer	4.98e-05	0.000308	CcSEcCtD
Everolimus—Pruritus—Paclitaxel—ovarian cancer	4.96e-05	0.000307	CcSEcCtD
Everolimus—Mental disorder—Epirubicin—ovarian cancer	4.94e-05	0.000306	CcSEcCtD
Everolimus—Erythema—Epirubicin—ovarian cancer	4.91e-05	0.000304	CcSEcCtD
Everolimus—Malnutrition—Epirubicin—ovarian cancer	4.91e-05	0.000304	CcSEcCtD
Everolimus—Feeling abnormal—Docetaxel—ovarian cancer	4.9e-05	0.000303	CcSEcCtD
Everolimus—Eye disorder—Doxorubicin—ovarian cancer	4.88e-05	0.000302	CcSEcCtD
Everolimus—Gastrointestinal pain—Docetaxel—ovarian cancer	4.86e-05	0.0003	CcSEcCtD
Everolimus—Flushing—Doxorubicin—ovarian cancer	4.84e-05	0.0003	CcSEcCtD
Everolimus—Cardiac disorder—Doxorubicin—ovarian cancer	4.84e-05	0.0003	CcSEcCtD
Everolimus—Flatulence—Epirubicin—ovarian cancer	4.84e-05	0.000299	CcSEcCtD
Everolimus—Dysgeusia—Epirubicin—ovarian cancer	4.81e-05	0.000297	CcSEcCtD
Everolimus—Diarrhoea—Paclitaxel—ovarian cancer	4.8e-05	0.000297	CcSEcCtD
Everolimus—Back pain—Epirubicin—ovarian cancer	4.75e-05	0.000294	CcSEcCtD
Everolimus—Angiopathy—Doxorubicin—ovarian cancer	4.74e-05	0.000293	CcSEcCtD
Everolimus—Muscle spasms—Epirubicin—ovarian cancer	4.72e-05	0.000292	CcSEcCtD
Everolimus—Immune system disorder—Doxorubicin—ovarian cancer	4.71e-05	0.000291	CcSEcCtD
Everolimus—Mediastinal disorder—Doxorubicin—ovarian cancer	4.7e-05	0.000291	CcSEcCtD
Everolimus—Body temperature increased—Docetaxel—ovarian cancer	4.7e-05	0.00029	CcSEcCtD
Everolimus—Abdominal pain—Docetaxel—ovarian cancer	4.7e-05	0.00029	CcSEcCtD
Everolimus—Chills—Doxorubicin—ovarian cancer	4.68e-05	0.00029	CcSEcCtD
Everolimus—Dizziness—Paclitaxel—ovarian cancer	4.64e-05	0.000287	CcSEcCtD
Everolimus—Vision blurred—Epirubicin—ovarian cancer	4.63e-05	0.000286	CcSEcCtD
Everolimus—Alopecia—Doxorubicin—ovarian cancer	4.61e-05	0.000285	CcSEcCtD
Everolimus—Mental disorder—Doxorubicin—ovarian cancer	4.57e-05	0.000283	CcSEcCtD
Everolimus—Ill-defined disorder—Epirubicin—ovarian cancer	4.56e-05	0.000282	CcSEcCtD
Everolimus—Erythema—Doxorubicin—ovarian cancer	4.54e-05	0.000281	CcSEcCtD
Everolimus—Malnutrition—Doxorubicin—ovarian cancer	4.54e-05	0.000281	CcSEcCtD
Everolimus—Anaemia—Epirubicin—ovarian cancer	4.54e-05	0.000281	CcSEcCtD
Everolimus—Agitation—Epirubicin—ovarian cancer	4.51e-05	0.000279	CcSEcCtD
Everolimus—Flatulence—Doxorubicin—ovarian cancer	4.48e-05	0.000277	CcSEcCtD
Everolimus—Vomiting—Paclitaxel—ovarian cancer	4.46e-05	0.000276	CcSEcCtD
Everolimus—Dysgeusia—Doxorubicin—ovarian cancer	4.45e-05	0.000275	CcSEcCtD
Everolimus—Malaise—Epirubicin—ovarian cancer	4.43e-05	0.000274	CcSEcCtD
Everolimus—Rash—Paclitaxel—ovarian cancer	4.42e-05	0.000273	CcSEcCtD
Everolimus—Dermatitis—Paclitaxel—ovarian cancer	4.42e-05	0.000273	CcSEcCtD
Everolimus—Syncope—Epirubicin—ovarian cancer	4.4e-05	0.000272	CcSEcCtD
Everolimus—Leukopenia—Epirubicin—ovarian cancer	4.4e-05	0.000272	CcSEcCtD
Everolimus—Back pain—Doxorubicin—ovarian cancer	4.39e-05	0.000272	CcSEcCtD
Everolimus—Headache—Paclitaxel—ovarian cancer	4.39e-05	0.000272	CcSEcCtD
Everolimus—Hypersensitivity—Docetaxel—ovarian cancer	4.38e-05	0.000271	CcSEcCtD
Everolimus—Muscle spasms—Doxorubicin—ovarian cancer	4.37e-05	0.00027	CcSEcCtD
Everolimus—Palpitations—Epirubicin—ovarian cancer	4.34e-05	0.000268	CcSEcCtD
Everolimus—Loss of consciousness—Epirubicin—ovarian cancer	4.32e-05	0.000267	CcSEcCtD
Everolimus—Cough—Epirubicin—ovarian cancer	4.28e-05	0.000265	CcSEcCtD
Everolimus—Vision blurred—Doxorubicin—ovarian cancer	4.28e-05	0.000265	CcSEcCtD
Everolimus—Asthenia—Docetaxel—ovarian cancer	4.26e-05	0.000264	CcSEcCtD
Everolimus—Convulsion—Epirubicin—ovarian cancer	4.25e-05	0.000263	CcSEcCtD
Everolimus—Hypertension—Epirubicin—ovarian cancer	4.24e-05	0.000262	CcSEcCtD
Everolimus—Ill-defined disorder—Doxorubicin—ovarian cancer	4.22e-05	0.000261	CcSEcCtD
Everolimus—Pruritus—Docetaxel—ovarian cancer	4.2e-05	0.00026	CcSEcCtD
Everolimus—Anaemia—Doxorubicin—ovarian cancer	4.2e-05	0.00026	CcSEcCtD
Everolimus—Arthralgia—Epirubicin—ovarian cancer	4.18e-05	0.000258	CcSEcCtD
Everolimus—Chest pain—Epirubicin—ovarian cancer	4.18e-05	0.000258	CcSEcCtD
Everolimus—Myalgia—Epirubicin—ovarian cancer	4.18e-05	0.000258	CcSEcCtD
Everolimus—Agitation—Doxorubicin—ovarian cancer	4.18e-05	0.000258	CcSEcCtD
Everolimus—Anxiety—Epirubicin—ovarian cancer	4.17e-05	0.000258	CcSEcCtD
Everolimus—Nausea—Paclitaxel—ovarian cancer	4.16e-05	0.000257	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	4.15e-05	0.000257	CcSEcCtD
Everolimus—Discomfort—Epirubicin—ovarian cancer	4.13e-05	0.000255	CcSEcCtD
Everolimus—Malaise—Doxorubicin—ovarian cancer	4.1e-05	0.000253	CcSEcCtD
Everolimus—Dry mouth—Epirubicin—ovarian cancer	4.09e-05	0.000253	CcSEcCtD
Everolimus—Syncope—Doxorubicin—ovarian cancer	4.07e-05	0.000252	CcSEcCtD
Everolimus—Leukopenia—Doxorubicin—ovarian cancer	4.07e-05	0.000251	CcSEcCtD
Everolimus—Diarrhoea—Docetaxel—ovarian cancer	4.07e-05	0.000251	CcSEcCtD
Everolimus—Palpitations—Doxorubicin—ovarian cancer	4.01e-05	0.000248	CcSEcCtD
Everolimus—Oedema—Epirubicin—ovarian cancer	4.01e-05	0.000248	CcSEcCtD
Everolimus—Loss of consciousness—Doxorubicin—ovarian cancer	3.99e-05	0.000247	CcSEcCtD
Everolimus—Infection—Epirubicin—ovarian cancer	3.98e-05	0.000246	CcSEcCtD
Everolimus—Cough—Doxorubicin—ovarian cancer	3.96e-05	0.000245	CcSEcCtD
Everolimus—Shock—Epirubicin—ovarian cancer	3.94e-05	0.000244	CcSEcCtD
Everolimus—Convulsion—Doxorubicin—ovarian cancer	3.94e-05	0.000243	CcSEcCtD
Everolimus—Nervous system disorder—Epirubicin—ovarian cancer	3.93e-05	0.000243	CcSEcCtD
Everolimus—Dizziness—Docetaxel—ovarian cancer	3.93e-05	0.000243	CcSEcCtD
Everolimus—Thrombocytopenia—Epirubicin—ovarian cancer	3.92e-05	0.000243	CcSEcCtD
Everolimus—Hypertension—Doxorubicin—ovarian cancer	3.92e-05	0.000243	CcSEcCtD
Everolimus—Tachycardia—Epirubicin—ovarian cancer	3.91e-05	0.000242	CcSEcCtD
Everolimus—Skin disorder—Epirubicin—ovarian cancer	3.89e-05	0.000241	CcSEcCtD
Everolimus—Hyperhidrosis—Epirubicin—ovarian cancer	3.87e-05	0.00024	CcSEcCtD
Everolimus—Arthralgia—Doxorubicin—ovarian cancer	3.87e-05	0.000239	CcSEcCtD
Everolimus—Myalgia—Doxorubicin—ovarian cancer	3.87e-05	0.000239	CcSEcCtD
Everolimus—Chest pain—Doxorubicin—ovarian cancer	3.87e-05	0.000239	CcSEcCtD
Everolimus—Anxiety—Doxorubicin—ovarian cancer	3.85e-05	0.000238	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	3.84e-05	0.000238	CcSEcCtD
Everolimus—Discomfort—Doxorubicin—ovarian cancer	3.82e-05	0.000236	CcSEcCtD
Everolimus—Anorexia—Epirubicin—ovarian cancer	3.82e-05	0.000236	CcSEcCtD
Everolimus—Dry mouth—Doxorubicin—ovarian cancer	3.78e-05	0.000234	CcSEcCtD
Everolimus—Vomiting—Docetaxel—ovarian cancer	3.78e-05	0.000234	CcSEcCtD
Everolimus—Rash—Docetaxel—ovarian cancer	3.75e-05	0.000232	CcSEcCtD
Everolimus—Hypotension—Epirubicin—ovarian cancer	3.74e-05	0.000232	CcSEcCtD
Everolimus—Dermatitis—Docetaxel—ovarian cancer	3.74e-05	0.000231	CcSEcCtD
Everolimus—Headache—Docetaxel—ovarian cancer	3.72e-05	0.00023	CcSEcCtD
Everolimus—Oedema—Doxorubicin—ovarian cancer	3.71e-05	0.000229	CcSEcCtD
Everolimus—Infection—Doxorubicin—ovarian cancer	3.68e-05	0.000228	CcSEcCtD
Everolimus—MTOR—Signaling by PDGF—PIK3CA—ovarian cancer	3.67e-05	0.000334	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Epirubicin—ovarian cancer	3.65e-05	0.000226	CcSEcCtD
Everolimus—Shock—Doxorubicin—ovarian cancer	3.65e-05	0.000226	CcSEcCtD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—ovarian cancer	3.64e-05	0.000331	CbGpPWpGaD
Everolimus—MTOR—Disease—SMARCA4—ovarian cancer	3.64e-05	0.000331	CbGpPWpGaD
Everolimus—Nervous system disorder—Doxorubicin—ovarian cancer	3.64e-05	0.000225	CcSEcCtD
Everolimus—Thrombocytopenia—Doxorubicin—ovarian cancer	3.63e-05	0.000224	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—PTEN—ovarian cancer	3.63e-05	0.000329	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	3.63e-05	0.000329	CbGpPWpGaD
Everolimus—Insomnia—Epirubicin—ovarian cancer	3.62e-05	0.000224	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—ovarian cancer	3.62e-05	0.000329	CbGpPWpGaD
Everolimus—Tachycardia—Doxorubicin—ovarian cancer	3.62e-05	0.000224	CcSEcCtD
Everolimus—MTOR—BDNF signaling pathway—AKT1—ovarian cancer	3.62e-05	0.000329	CbGpPWpGaD
Everolimus—Skin disorder—Doxorubicin—ovarian cancer	3.6e-05	0.000223	CcSEcCtD
Everolimus—Paraesthesia—Epirubicin—ovarian cancer	3.6e-05	0.000223	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—IL6—ovarian cancer	3.59e-05	0.000326	CbGpPWpGaD
Everolimus—Hyperhidrosis—Doxorubicin—ovarian cancer	3.58e-05	0.000222	CcSEcCtD
Everolimus—Dyspnoea—Epirubicin—ovarian cancer	3.57e-05	0.000221	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR—IL6—ovarian cancer	3.57e-05	0.000324	CbGpPWpGaD
Everolimus—Somnolence—Epirubicin—ovarian cancer	3.56e-05	0.00022	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB2—IL6—ovarian cancer	3.55e-05	0.000323	CbGpPWpGaD
Everolimus—MTOR—Disease—EREG—ovarian cancer	3.55e-05	0.000323	CbGpPWpGaD
Everolimus—FKBP1A—Disease—TERT—ovarian cancer	3.55e-05	0.000322	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—IL6—ovarian cancer	3.53e-05	0.000321	CbGpPWpGaD
Everolimus—Anorexia—Doxorubicin—ovarian cancer	3.53e-05	0.000219	CcSEcCtD
Everolimus—Nausea—Docetaxel—ovarian cancer	3.53e-05	0.000218	CcSEcCtD
Everolimus—Dyspepsia—Epirubicin—ovarian cancer	3.53e-05	0.000218	CcSEcCtD
Everolimus—MTOR—Downstream signaling of activated FGFR—AKT1—ovarian cancer	3.52e-05	0.00032	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—VEGFA—ovarian cancer	3.49e-05	0.000317	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—ovarian cancer	3.48e-05	0.000316	CbGpPWpGaD
Everolimus—Decreased appetite—Epirubicin—ovarian cancer	3.48e-05	0.000215	CcSEcCtD
Everolimus—MTOR—B Cell Activation—PIK3CA—ovarian cancer	3.48e-05	0.000316	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—HRAS—ovarian cancer	3.47e-05	0.000316	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—ovarian cancer	3.47e-05	0.000316	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—HRAS—ovarian cancer	3.47e-05	0.000316	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—AKT1—ovarian cancer	3.47e-05	0.000315	CbGpPWpGaD
Everolimus—Hypotension—Doxorubicin—ovarian cancer	3.46e-05	0.000214	CcSEcCtD
Everolimus—Gastrointestinal disorder—Epirubicin—ovarian cancer	3.46e-05	0.000214	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—STAT3—ovarian cancer	3.46e-05	0.000314	CbGpPWpGaD
Everolimus—Fatigue—Epirubicin—ovarian cancer	3.45e-05	0.000214	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—HRAS—ovarian cancer	3.44e-05	0.000313	CbGpPWpGaD
Everolimus—Pain—Epirubicin—ovarian cancer	3.43e-05	0.000212	CcSEcCtD
Everolimus—Constipation—Epirubicin—ovarian cancer	3.43e-05	0.000212	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—HRAS—ovarian cancer	3.41e-05	0.00031	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—HRAS—ovarian cancer	3.4e-05	0.000309	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—TLR4—ovarian cancer	3.39e-05	0.000308	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	3.38e-05	0.000209	CcSEcCtD
Everolimus—Insomnia—Doxorubicin—ovarian cancer	3.35e-05	0.000207	CcSEcCtD
Everolimus—Paraesthesia—Doxorubicin—ovarian cancer	3.33e-05	0.000206	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PIK3CA—ovarian cancer	3.33e-05	0.000302	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—AKT1—ovarian cancer	3.33e-05	0.000302	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—ovarian cancer	3.33e-05	0.000302	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—IL6—ovarian cancer	3.33e-05	0.000302	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—IL6—ovarian cancer	3.33e-05	0.000302	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—AKT1—ovarian cancer	3.31e-05	0.000301	CbGpPWpGaD
Everolimus—Dyspnoea—Doxorubicin—ovarian cancer	3.31e-05	0.000204	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—MAPK3—ovarian cancer	3.3e-05	0.0003	CbGpPWpGaD
Everolimus—Feeling abnormal—Epirubicin—ovarian cancer	3.3e-05	0.000204	CcSEcCtD
Everolimus—Somnolence—Doxorubicin—ovarian cancer	3.3e-05	0.000204	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—IL6—ovarian cancer	3.3e-05	0.000299	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—ovarian cancer	3.29e-05	0.000299	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—AKT1—ovarian cancer	3.29e-05	0.000299	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CAV1—ovarian cancer	3.28e-05	0.000298	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—AKT1—ovarian cancer	3.28e-05	0.000298	CbGpPWpGaD
Everolimus—Gastrointestinal pain—Epirubicin—ovarian cancer	3.28e-05	0.000203	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—IL6—ovarian cancer	3.27e-05	0.000297	CbGpPWpGaD
Everolimus—Dyspepsia—Doxorubicin—ovarian cancer	3.26e-05	0.000202	CcSEcCtD
Everolimus—MTOR—DAP12 signaling—AKT1—ovarian cancer	3.26e-05	0.000296	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—IL6—ovarian cancer	3.25e-05	0.000295	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IL6ST—ovarian cancer	3.25e-05	0.000295	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—STAT3—ovarian cancer	3.24e-05	0.000295	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—NRAS—ovarian cancer	3.24e-05	0.000294	CbGpPWpGaD
Everolimus—Decreased appetite—Doxorubicin—ovarian cancer	3.22e-05	0.000199	CcSEcCtD
Everolimus—MTOR—B Cell Activation—HRAS—ovarian cancer	3.22e-05	0.000292	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—ovarian cancer	3.21e-05	0.000292	CbGpPWpGaD
Everolimus—Gastrointestinal disorder—Doxorubicin—ovarian cancer	3.2e-05	0.000198	CcSEcCtD
Everolimus—Fatigue—Doxorubicin—ovarian cancer	3.2e-05	0.000198	CcSEcCtD
Everolimus—Constipation—Doxorubicin—ovarian cancer	3.17e-05	0.000196	CcSEcCtD
Everolimus—Pain—Doxorubicin—ovarian cancer	3.17e-05	0.000196	CcSEcCtD
Everolimus—Abdominal pain—Epirubicin—ovarian cancer	3.17e-05	0.000196	CcSEcCtD
Everolimus—Body temperature increased—Epirubicin—ovarian cancer	3.17e-05	0.000196	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—MAPK1—ovarian cancer	3.14e-05	0.000286	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PPP2R1A—ovarian cancer	3.12e-05	0.000284	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IL6ST—ovarian cancer	3.11e-05	0.000282	CbGpPWpGaD
Everolimus—MTOR—Disease—FASN—ovarian cancer	3.11e-05	0.000282	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—MAPK3—ovarian cancer	3.1e-05	0.000281	CbGpPWpGaD
Everolimus—MTOR—Disease—PARP1—ovarian cancer	3.09e-05	0.000281	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—ovarian cancer	3.08e-05	0.00028	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—AKT1—ovarian cancer	3.07e-05	0.000279	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—AKT1—ovarian cancer	3.07e-05	0.000279	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—ovarian cancer	3.07e-05	0.000279	CbGpPWpGaD
Everolimus—Feeling abnormal—Doxorubicin—ovarian cancer	3.06e-05	0.000189	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—AKT1—ovarian cancer	3.04e-05	0.000276	CbGpPWpGaD
Everolimus—Gastrointestinal pain—Doxorubicin—ovarian cancer	3.03e-05	0.000187	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—HDAC6—ovarian cancer	3.02e-05	0.000274	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—AKT1—ovarian cancer	3.01e-05	0.000274	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—AKT1—ovarian cancer	3e-05	0.000273	CbGpPWpGaD
Everolimus—FKBP1A—Disease—APC—ovarian cancer	2.99e-05	0.000271	CbGpPWpGaD
Everolimus—Hypersensitivity—Epirubicin—ovarian cancer	2.95e-05	0.000183	CcSEcCtD
Everolimus—MTOR—Disease—SLC2A1—ovarian cancer	2.95e-05	0.000268	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—MAPK1—ovarian cancer	2.95e-05	0.000268	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—EGFR—ovarian cancer	2.95e-05	0.000268	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—ovarian cancer	2.95e-05	0.000268	CbGpPWpGaD
Everolimus—Body temperature increased—Doxorubicin—ovarian cancer	2.93e-05	0.000181	CcSEcCtD
Everolimus—Abdominal pain—Doxorubicin—ovarian cancer	2.93e-05	0.000181	CcSEcCtD
Everolimus—Asthenia—Epirubicin—ovarian cancer	2.88e-05	0.000178	CcSEcCtD
Everolimus—MTOR—B Cell Activation—AKT1—ovarian cancer	2.84e-05	0.000258	CbGpPWpGaD
Everolimus—Pruritus—Epirubicin—ovarian cancer	2.84e-05	0.000175	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—KRAS—ovarian cancer	2.78e-05	0.000253	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CDH1—ovarian cancer	2.76e-05	0.000251	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PIK3CD—ovarian cancer	2.75e-05	0.000249	CbGpPWpGaD
Everolimus—Diarrhoea—Epirubicin—ovarian cancer	2.74e-05	0.00017	CcSEcCtD
Everolimus—Hypersensitivity—Doxorubicin—ovarian cancer	2.73e-05	0.000169	CcSEcCtD
Everolimus—MTOR—Immune System—PPP2R1A—ovarian cancer	2.72e-05	0.000247	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—ovarian cancer	2.72e-05	0.000247	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—YAP1—ovarian cancer	2.67e-05	0.000242	CbGpPWpGaD
Everolimus—Asthenia—Doxorubicin—ovarian cancer	2.66e-05	0.000165	CcSEcCtD
Everolimus—Dizziness—Epirubicin—ovarian cancer	2.65e-05	0.000164	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—TP53—ovarian cancer	2.64e-05	0.00024	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PIK3CD—ovarian cancer	2.64e-05	0.00024	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PIK3CD—ovarian cancer	2.63e-05	0.000239	CbGpPWpGaD
Everolimus—Pruritus—Doxorubicin—ovarian cancer	2.62e-05	0.000162	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—XIAP—ovarian cancer	2.61e-05	0.000238	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—PIK3CA—ovarian cancer	2.56e-05	0.000232	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SMARCA4—ovarian cancer	2.55e-05	0.000231	CbGpPWpGaD
Everolimus—Vomiting—Epirubicin—ovarian cancer	2.55e-05	0.000158	CcSEcCtD
Everolimus—Diarrhoea—Doxorubicin—ovarian cancer	2.54e-05	0.000157	CcSEcCtD
Everolimus—Rash—Epirubicin—ovarian cancer	2.53e-05	0.000156	CcSEcCtD
Everolimus—Dermatitis—Epirubicin—ovarian cancer	2.52e-05	0.000156	CcSEcCtD
Everolimus—Headache—Epirubicin—ovarian cancer	2.51e-05	0.000155	CcSEcCtD
Everolimus—MTOR—Disease—PPP2R1A—ovarian cancer	2.51e-05	0.000228	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EREG—ovarian cancer	2.49e-05	0.000226	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TERT—ovarian cancer	2.48e-05	0.000226	CbGpPWpGaD
Everolimus—Dizziness—Doxorubicin—ovarian cancer	2.45e-05	0.000152	CcSEcCtD
Everolimus—MTOR—Innate Immune System—ERBB2—ovarian cancer	2.43e-05	0.00022	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD8A—ovarian cancer	2.42e-05	0.00022	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—IL6—ovarian cancer	2.42e-05	0.000219	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PIK3CB—ovarian cancer	2.39e-05	0.000217	CbGpPWpGaD
Everolimus—Nausea—Epirubicin—ovarian cancer	2.38e-05	0.000147	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—HRAS—ovarian cancer	2.37e-05	0.000215	CbGpPWpGaD
Everolimus—Vomiting—Doxorubicin—ovarian cancer	2.36e-05	0.000146	CcSEcCtD
Everolimus—Rash—Doxorubicin—ovarian cancer	2.34e-05	0.000145	CcSEcCtD
Everolimus—Dermatitis—Doxorubicin—ovarian cancer	2.34e-05	0.000144	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—PGR—ovarian cancer	2.33e-05	0.000212	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—ERBB2—ovarian cancer	2.33e-05	0.000212	CbGpPWpGaD
Everolimus—Headache—Doxorubicin—ovarian cancer	2.32e-05	0.000144	CcSEcCtD
Everolimus—FKBP1A—Disease—ERBB2—ovarian cancer	2.32e-05	0.000211	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PIK3CB—ovarian cancer	2.3e-05	0.000209	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CAV1—ovarian cancer	2.3e-05	0.000209	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PIK3CB—ovarian cancer	2.29e-05	0.000208	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MTOR—ovarian cancer	2.29e-05	0.000208	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—IL6—ovarian cancer	2.27e-05	0.000206	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CDKN1B—ovarian cancer	2.25e-05	0.000204	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NME2—ovarian cancer	2.24e-05	0.000204	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ESR1—ovarian cancer	2.21e-05	0.000201	CbGpPWpGaD
Everolimus—Nausea—Doxorubicin—ovarian cancer	2.2e-05	0.000136	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—IL6ST—ovarian cancer	2.18e-05	0.000198	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PARP1—ovarian cancer	2.17e-05	0.000197	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CDKN1B—ovarian cancer	2.16e-05	0.000196	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CDKN1B—ovarian cancer	2.15e-05	0.000195	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CTNNB1—ovarian cancer	2.12e-05	0.000193	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—APC—ovarian cancer	2.09e-05	0.00019	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CG—ovarian cancer	2.09e-05	0.00019	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—AKT1—ovarian cancer	2.09e-05	0.00019	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PTEN—ovarian cancer	2.07e-05	0.000188	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CTNNB1—ovarian cancer	2.03e-05	0.000184	CbGpPWpGaD
Everolimus—MTOR—Disease—TERT—ovarian cancer	1.99e-05	0.000181	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PTEN—ovarian cancer	1.99e-05	0.00018	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PTEN—ovarian cancer	1.98e-05	0.00018	CbGpPWpGaD
Everolimus—MTOR—Immune System—TLR4—ovarian cancer	1.98e-05	0.000179	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6ST—ovarian cancer	1.89e-05	0.000172	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—NRAS—ovarian cancer	1.85e-05	0.000168	CbGpPWpGaD
Everolimus—MTOR—Disease—CAV1—ovarian cancer	1.84e-05	0.000168	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CD—ovarian cancer	1.84e-05	0.000167	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—NRAS—ovarian cancer	1.77e-05	0.000161	CbGpPWpGaD
Everolimus—FKBP1A—Disease—STAT3—ovarian cancer	1.77e-05	0.000161	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—MAPK3—ovarian cancer	1.77e-05	0.000161	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NRAS—ovarian cancer	1.76e-05	0.00016	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PPP2R1A—ovarian cancer	1.76e-05	0.00016	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6ST—ovarian cancer	1.75e-05	0.000159	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MAPK3—ovarian cancer	1.69e-05	0.000153	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—MAPK1—ovarian cancer	1.68e-05	0.000153	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—EGFR—ovarian cancer	1.68e-05	0.000153	CbGpPWpGaD
Everolimus—MTOR—Disease—APC—ovarian cancer	1.68e-05	0.000153	CbGpPWpGaD
Everolimus—MTOR—Immune System—CDH1—ovarian cancer	1.67e-05	0.000152	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MYC—ovarian cancer	1.64e-05	0.000149	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ERBB2—ovarian cancer	1.62e-05	0.000148	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—EGFR—ovarian cancer	1.61e-05	0.000147	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MAPK1—ovarian cancer	1.61e-05	0.000146	CbGpPWpGaD
Everolimus—FKBP1A—Disease—EGFR—ovarian cancer	1.61e-05	0.000146	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MTOR—ovarian cancer	1.6e-05	0.000146	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CB—ovarian cancer	1.6e-05	0.000146	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CD—ovarian cancer	1.6e-05	0.000145	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—KRAS—ovarian cancer	1.59e-05	0.000144	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CXCL8—ovarian cancer	1.54e-05	0.00014	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—KRAS—ovarian cancer	1.53e-05	0.000139	CbGpPWpGaD
Everolimus—FKBP1A—Disease—KRAS—ovarian cancer	1.52e-05	0.000138	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CDKN1B—ovarian cancer	1.5e-05	0.000137	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3CD—ovarian cancer	1.48e-05	0.000134	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CASP3—ovarian cancer	1.47e-05	0.000134	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL2—ovarian cancer	1.47e-05	0.000134	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PIK3CA—ovarian cancer	1.46e-05	0.000133	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYTB—ovarian cancer	1.44e-05	0.000131	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCND1—ovarian cancer	1.43e-05	0.00013	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CTNNB1—ovarian cancer	1.42e-05	0.000129	CbGpPWpGaD
Everolimus—MTOR—Immune System—ERBB2—ovarian cancer	1.41e-05	0.000128	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PIK3CA—ovarian cancer	1.4e-05	0.000127	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TERT—ovarian cancer	1.4e-05	0.000127	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PIK3CA—ovarian cancer	1.4e-05	0.000127	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CB—ovarian cancer	1.39e-05	0.000127	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MMP9—ovarian cancer	1.39e-05	0.000127	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PTEN—ovarian cancer	1.38e-05	0.000126	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—HRAS—ovarian cancer	1.35e-05	0.000123	CbGpPWpGaD
Everolimus—MTOR—Immune System—CDKN1B—ovarian cancer	1.31e-05	0.000119	CbGpPWpGaD
Everolimus—MTOR—Disease—ERBB2—ovarian cancer	1.3e-05	0.000118	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HRAS—ovarian cancer	1.3e-05	0.000118	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IL6—ovarian cancer	1.29e-05	0.000117	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CAV1—ovarian cancer	1.29e-05	0.000117	CbGpPWpGaD
Everolimus—FKBP1A—Disease—HRAS—ovarian cancer	1.29e-05	0.000117	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3CB—ovarian cancer	1.29e-05	0.000117	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL2—ovarian cancer	1.28e-05	0.000116	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—BRIP1—ovarian cancer	1.26e-05	0.000115	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPP1CC—ovarian cancer	1.26e-05	0.000115	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—VEGFA—ovarian cancer	1.25e-05	0.000114	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ESR1—ovarian cancer	1.24e-05	0.000113	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—STAT3—ovarian cancer	1.24e-05	0.000113	CbGpPWpGaD
Everolimus—MTOR—Immune System—CTNNB1—ovarian cancer	1.24e-05	0.000112	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NRAS—ovarian cancer	1.24e-05	0.000112	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IL6—ovarian cancer	1.24e-05	0.000112	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6ST—ovarian cancer	1.22e-05	0.000111	CbGpPWpGaD
Everolimus—MTOR—Disease—CDKN1B—ovarian cancer	1.21e-05	0.00011	CbGpPWpGaD
Everolimus—MTOR—Immune System—PTEN—ovarian cancer	1.2e-05	0.000109	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—AKT1—ovarian cancer	1.19e-05	0.000108	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MAPK3—ovarian cancer	1.18e-05	0.000107	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CG—ovarian cancer	1.18e-05	0.000107	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APC—ovarian cancer	1.18e-05	0.000107	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MYC—ovarian cancer	1.15e-05	0.000105	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—AKT1—ovarian cancer	1.14e-05	0.000104	CbGpPWpGaD
Everolimus—MTOR—Disease—CTNNB1—ovarian cancer	1.14e-05	0.000104	CbGpPWpGaD
Everolimus—FKBP1A—Disease—AKT1—ovarian cancer	1.14e-05	0.000104	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MAPK1—ovarian cancer	1.13e-05	0.000102	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EGFR—ovarian cancer	1.13e-05	0.000102	CbGpPWpGaD
Everolimus—MTOR—Disease—PTEN—ovarian cancer	1.11e-05	0.000101	CbGpPWpGaD
Everolimus—MTOR—Immune System—STAT3—ovarian cancer	1.08e-05	9.79e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—NRAS—ovarian cancer	1.07e-05	9.76e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KRAS—ovarian cancer	1.06e-05	9.66e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CD—ovarian cancer	1.03e-05	9.39e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—MAPK3—ovarian cancer	1.03e-05	9.35e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—STAT3—ovarian cancer	9.95e-06	9.04e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—NRAS—ovarian cancer	9.92e-06	9.01e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—MAPK1—ovarian cancer	9.79e-06	8.9e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—EGFR—ovarian cancer	9.79e-06	8.89e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CA—ovarian cancer	9.77e-06	8.87e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—MAPK3—ovarian cancer	9.5e-06	8.63e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—ovarian cancer	9.45e-06	8.59e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—KRAS—ovarian cancer	9.25e-06	8.4e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—MYC—ovarian cancer	9.24e-06	8.4e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ERBB2—ovarian cancer	9.13e-06	8.3e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—MAPK1—ovarian cancer	9.04e-06	8.21e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—EGFR—ovarian cancer	9.04e-06	8.21e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HRAS—ovarian cancer	9.04e-06	8.21e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CB—ovarian cancer	9.01e-06	8.19e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCL8—ovarian cancer	8.66e-06	7.87e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6—ovarian cancer	8.65e-06	7.86e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—KRAS—ovarian cancer	8.54e-06	7.76e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CA—ovarian cancer	8.5e-06	7.72e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—YAP1—ovarian cancer	8.47e-06	7.69e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CDKN1B—ovarian cancer	8.46e-06	7.68e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CASP3—ovarian cancer	8.29e-06	7.53e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL2—ovarian cancer	8.28e-06	7.52e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCND1—ovarian cancer	8.07e-06	7.33e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CTNNB1—ovarian cancer	7.99e-06	7.26e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AKT1—ovarian cancer	7.98e-06	7.25e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—HRAS—ovarian cancer	7.86e-06	7.14e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3CA—ovarian cancer	7.85e-06	7.13e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MMP9—ovarian cancer	7.83e-06	7.12e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTEN—ovarian cancer	7.79e-06	7.08e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6—ovarian cancer	7.53e-06	6.84e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—HRAS—ovarian cancer	7.26e-06	6.59e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VEGFA—ovarian cancer	7.04e-06	6.39e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—STAT3—ovarian cancer	6.97e-06	6.33e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NRAS—ovarian cancer	6.95e-06	6.31e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6—ovarian cancer	6.95e-06	6.31e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—AKT1—ovarian cancer	6.94e-06	6.31e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—FASN—ovarian cancer	6.9e-06	6.27e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC5A5—ovarian cancer	6.79e-06	6.17e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MAPK3—ovarian cancer	6.66e-06	6.05e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC2A1—ovarian cancer	6.56e-06	5.96e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MYC—ovarian cancer	6.47e-06	5.88e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—AKT1—ovarian cancer	6.41e-06	5.82e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MAPK1—ovarian cancer	6.33e-06	5.75e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EGFR—ovarian cancer	6.33e-06	5.75e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP1B1—ovarian cancer	6.29e-06	5.71e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KRAS—ovarian cancer	5.98e-06	5.43e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	5.57e-06	5.06e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CA—ovarian cancer	5.49e-06	4.99e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—ovarian cancer	5.32e-06	4.83e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ABCB1—ovarian cancer	5.18e-06	4.7e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TYMS—ovarian cancer	5.08e-06	4.62e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HRAS—ovarian cancer	5.08e-06	4.62e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6—ovarian cancer	4.87e-06	4.42e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKT1—ovarian cancer	4.49e-06	4.08e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CAV1—ovarian cancer	4.1e-06	3.72e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CG—ovarian cancer	3.73e-06	3.39e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CD—ovarian cancer	3.28e-06	2.98e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CB—ovarian cancer	2.86e-06	2.6e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTEN—ovarian cancer	2.47e-06	2.24e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.74e-06	1.58e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKT1—ovarian cancer	1.42e-06	1.29e-05	CbGpPWpGaD
